BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Abstract excerpt

Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease to treat. Despite advances in surgical techniques, radiation, and medical therapies, the 5-year survival rate remains below 9%. Over the past decade, the genomic landscape of PDAC has been well studied and BRCA mutations have emerged as a target for the development of more effective therapies. Alterations in germline BRCA and PALB2...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to Cancer Genomics and Diagnostics
• Share to PARP inhibition in cancer therapy